8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Mar 13, 2026·SEC
Equillium, Inc.(EQ)Earnings, Financials & Key Ratios
EQ•NASDAQ
Price updated Jun 11, 2026
AboutEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Show more
- Revenue$0-100.0%
- EBITDA-$24M-189.2%
- Net Income-$22M-177.6%
- EPS (Diluted)-0.39-69.6%
- ROE-93.99%-142.6%
- ROIC-8884.96%-1003.9%
- Debt/Equity0.03+24.8%
EQ Key Insights
Equillium, Inc. (EQ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 96 (top 4%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EQ posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EQ Price & Volume
Equillium, Inc. (EQ) stock price & volume — 10-year historical chart
Loading chart...
EQ Growth Metrics
Equillium, Inc. (EQ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-36.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM2.87%
Return on Capital
10 Years-52.26%
5 Years-65.81%
3 Years-59.71%
Last Year-98.06%
EQ Recent Earnings
Equillium, Inc. (EQ) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (83%)
Q2 2026Latest
May 13, 2026EPS
$0.06
Est $0.04
-50.0%
Revenue
—
Q2 2026
Mar 25, 2026EPS
$0.04
Est $0.07
+42.9%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.06
Est $0.14
+57.1%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.16
Est $0.14
-14.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.06vs $0.04-50.0% | — |
| Q2 2026 | Mar 25, 2026 | $0.04vs $0.07+42.9% | — |
| Q4 2025 | Nov 13, 2025 | $0.06vs $0.14+57.1% | — |
| Q3 2025 | Aug 14, 2025 | $0.16vs $0.14-14.3% | — |
Based on last 12 quarters of dataView full earnings history →
EQ Peer Comparison
Equillium, Inc. (EQ) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 CABA | 490.79M | 3.01 | -1.84 | -131.58% | 0.24 | |||
 KMDA | 429.18M | 7.44 | 20.11 | 12.12% | 11.21% | 7.73% | 0.04 | |
 RAPT | 295.54M | 58.01 | -2.28 | -61.81% | 0.02 | |||
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 RXST | 198.7M | 4.80 | -5.05 | -3.89% | -36.58% | -17.01% | 0.04 | |
 ACLX | 6.73B | 115.07 | -28.27 | -79.35% | -10.27% | -55.42% | 0.24 |
Compare EQ vs Peers
Equillium, Inc. (EQ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EQ Income Statement
Equillium, Inc. (EQ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 15.76M | 36.08M | 41.09M | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | 128.97% | 13.89% | -100% | -100% |
Cost of Goods Sold | 122 | 6.1K | 23K | 45K | 0 | 0 | 0 | 0 | 116K | 79K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -122▲ 0% | -6.1K▼ 4901.6% | -23K▼ 276.9% | -45K▼ 95.7% | 0▲ 100.0% | 15.76M▲ 0% | 36.08M▲ 129.0% | 41.09M▲ 13.9% | -116K▼ 100.3% | -79K▲ 0% |
Gross Margin % | - | - | - | - | - | 100% | 100% | 100% | - | - |
Gross Profit Growth % | - | -4901.64% | -276.93% | -95.65% | 100% | - | 128.97% | 13.89% | -100.28% | - |
Operating Expenses | 1.71M | 8.62M | 26.73M | 29.5M | 37.79M | 77.83M | 50.61M | 49.36M | 23.63M | 20.3M |
OpEx % of Revenue | - | - | - | - | - | 493.91% | 140.25% | 120.12% | - | - |
Selling, General & Admin | 378.21K | 3.67M | 9.09M | 10.12M | 11.41M | 17.24M | 13.57M | 11.94M | 10.79M | 10.46M |
SG&A % of Revenue | - | - | - | - | - | 109.39% | 37.6% | 29.04% | - | - |
Research & Development | 1.33M | 4.94M | 17.64M | 19.38M | 26.38M | 37.55M | 37.04M | 37.43M | 12.84M | 9.91M |
R&D % of Revenue | - | - | - | - | - | 238.26% | 102.65% | 91.08% | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 23.05M | 0 | 0 | 0 | -79K |
Operating Income | -1.71M▲ 0% | -8.62M▼ 403.2% | -26.73M▼ 210.2% | -29.55M▼ 10.6% | -37.79M▼ 27.9% | -62.08M▼ 64.3% | -14.52M▲ 76.6% | -8.27M▲ 43.1% | -23.63M▼ 185.8% | -20.38M▲ 0% |
Operating Margin % | - | - | - | - | - | -393.91% | -40.24% | -20.12% | - | - |
Operating Income Growth % | - | -403.2% | -210.24% | -10.55% | -27.88% | -64.28% | 76.61% | 43.06% | -185.81% | - |
EBITDA | -1.71M | -8.61M | -26.7M | -29.5M | -37.71M | -61.96M | -14.4M | -8.13M | -23.52M | -20.27M |
EBITDA Margin % | - | - | - | - | - | -393.16% | -39.9% | -19.79% | - | - |
EBITDA Growth % | - | -402.88% | -210.19% | -10.48% | -27.83% | -64.28% | 76.76% | 43.51% | -189.2% | -42.64% |
D&A (Non-Cash Add-back) | 122 | 6.1K | 23K | 45K | 72K | 118K | 126K | 137K | 116K | 107K |
EBIT | -1.88M | -10.69M | -25.32M | -28.71M | -37.98M | -61.38M | -12.26M | -7.71M | -23.63M | -20.38M |
Net Interest Income | 0 | -2.22M | 1.11M | -623K | -1.02M | -633K | 1.84M | 1.38M | 833K | 969K |
Interest Income | 0 | 339.62K | 1.39M | 476K | 57K | 420K | 2.33M | 1.38M | 833K | 969K |
Interest Expense | 379.38K | 2.56M | 279K | 1.1M | 1.07M | 1.05M | 491K | 0 | 0 | 0 |
Other Income/Expense | -549.82K | -4.63M | 1.13M | -265K | -1.27M | -352K | 1.77M | 563K | 1.24M | 1.32M |
Pretax Income | -2.26M▲ 0% | -13.25M▼ 485.8% | -25.6M▼ 93.2% | -29.81M▼ 16.5% | -39.05M▼ 31.0% | -62.43M▼ 59.9% | -12.76M▲ 79.6% | -7.71M▲ 39.6% | -22.4M▼ 190.7% | -19.05M▲ 0% |
Pretax Margin % | - | - | - | - | - | -396.14% | -35.35% | -18.75% | - | - |
Income Tax | -2 | 140.51K | 0 | 0 | 0 | 0 | 580K | 361K | 0 | 0 |
Effective Tax Rate % | 0% | -1.06% | 0% | 0% | 0% | 0% | -4.55% | -4.68% | 0% | 0% |
Net Income | -2.26M▲ 0% | -13.25M▼ 485.8% | -25.58M▼ 93.0% | -29.81M▼ 16.6% | -38.98M▼ 30.7% | -62.43M▼ 60.2% | -13.34M▲ 78.6% | -8.07M▲ 39.5% | -22.4M▼ 177.6% | -19.05M▲ 0% |
Net Margin % | - | - | - | - | - | -396.14% | -36.96% | -19.63% | - | - |
Net Income Growth % | - | -485.8% | -93.03% | -16.56% | -30.75% | -60.15% | 78.64% | 39.51% | -177.65% | -36.23% |
Net Income (Continuing) | -2.26M | -13.25M | -25.6M | -29.81M | -39.05M | -62.43M | -13.34M | -8.07M | -22.4M | -19.05M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.19▲ 0% | -1.09▼ 473.7% | -1.47▼ 34.9% | -1.46▲ 0.7% | -1.35▲ 7.5% | -3.19▼ 136.3% | -0.38▲ 88.1% | -0.23▲ 39.5% | -0.39▼ 69.6% | -0.20▲ 0% |
EPS Growth % | - | -473.68% | -34.86% | 0.68% | 7.53% | -136.3% | 88.09% | 39.47% | -69.57% | 2.87% |
EPS (Basic) | -0.13 | -1.09 | -1.47 | -1.46 | -1.35 | -3.19 | -0.38 | -0.23 | -0.39 | - |
Diluted Shares Outstanding | 11.68M | 12.19M | 17.38M | 20.36M | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M | 96.28M |
Basic Shares Outstanding | 11.68M | 12.19M | 17.38M | 20.36M | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M | 96.28M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EQ Balance Sheet
Equillium, Inc. (EQ) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.15M | 67.16M | 55.54M | 85.17M | 83.37M | 76.73M | 49.35M | 24.98M | 30.28M | 62.27M |
Cash & Short-Term Investments | 7.1M | 65.91M | 53.14M | 82.16M | 80.71M | 71.02M | 40.87M | 22.57M | 30.28M | 61.32M |
Cash Only | 7.1M | 28.51M | 13.22M | 23.98M | 50.37M | 59.11M | 23.22M | 18.09M | 30.28M | 61.32M |
Short-Term Investments | 0 | 37.4M | 39.92M | 58.18M | 30.34M | 11.92M | 17.65M | 4.49M | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 4.11M | 6.29M | 1.14M | 108K | 0 |
Days Sales Outstanding | - | - | - | - | - | 95.26 | 63.58 | 10.16 | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 8K | 235K | 429K | -547K | 953K |
Total Non-Current Assets | 2.08K | 63.52K | 108K | 254K | 2.04M | 1.69M | 1.18M | 626K | 658K | 808K |
Property, Plant & Equipment | 2.08K | 63.52K | 93K | 239K | 1.88M | 1.58M | 1.11M | 626K | 658K | 781K |
Fixed Asset Turnover | - | - | - | - | - | 9.96x | 32.48x | 65.65x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | -93K | 15K | 153K | 104K | 70K | 0 | 0 | 27K |
Total Assets | 7.15M▲ 0% | 67.16M▲ 839.2% | 55.54M▼ 17.3% | 85.43M▲ 53.8% | 85.41M▼ 0.0% | 78.42M▼ 8.2% | 50.53M▼ 35.6% | 25.6M▼ 49.3% | 31.89M▲ 24.5% | 63.08M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.20x | 0.71x | 1.61x | - | 0.00x |
Asset Growth % | - | 839.15% | -17.31% | 53.82% | -0.03% | -8.18% | -35.57% | -49.33% | 24.54% | 230.7% |
Total Current Liabilities | 568.82K | 2.03M | 3.88M | 7.25M | 8.91M | 32.04M | 27.57M | 6.36M | 2.93M | 3.35M |
Accounts Payable | 243.74K | 1.12M | 1.87M | 2.77M | 1.23M | 3.98M | 4.71M | 2.68M | 755K | 1.29M |
Days Payables Outstanding | 729.23K | 66.93K | 29.72K | 22.44K | - | - | - | - | 2.38K | 9.18K |
Short-Term Debt | 0 | 0 | 0 | 1.67M | 1.43M | 5.71M | 0 | 197K | 363K | 441K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 14.7M | 15.73M | 0 | 0 | 0 |
Other Current Liabilities | 0 | 349.46K | 795K | 0 | 3.38M | 0 | 3.64M | 2.68M | 1.82M | 1.61M |
Current Ratio | 12.57x | 33.12x | 14.30x | 11.76x | 9.35x | 2.40x | 1.79x | 3.93x | 10.32x | 18.62x |
Quick Ratio | 12.57x | 33.12x | 14.30x | 11.76x | 9.35x | 2.40x | 1.79x | 3.93x | 10.32x | 18.62x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 8.83M | 200K | 9.81M | 8.33M | 9.98M | 14.44M | 384K | 187K | 356K | 251K |
Long-Term Debt | 8.06M | 0 | 9.68M | 8.28M | 8.75M | 3.24M | 0 | 0 | 356K | 251K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.24M | 824K | 384K | 187K | 0 | 109K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 775.84K | 0 | 127K | 54K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 9.4M | 2.23M | 13.69M | 15.57M | 18.9M | 46.48M | 27.96M | 6.54M | 3.29M | 3.6M |
Total Debt | 8.06M | 200K | 9.68M | 9.94M | 11.79M | 10.19M | 824K | 384K | 719K | 692K |
Net Debt | 955.31K | -28.31M | -3.54M | -14.04M | -38.58M | -48.92M | -22.39M | -17.7M | -29.56M | -60.63M |
Debt / Equity | - | 0.00x | 0.23x | 0.14x | 0.18x | 0.32x | 0.04x | 0.02x | 0.03x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 2.99x |
Interest Coverage | -4.96x | -4.18x | -90.76x | -26.13x | -35.40x | -58.29x | -24.98x | - | - | - |
Total Equity | -2.25M▲ 0% | 64.94M▲ 2983.3% | 41.85M▼ 35.6% | 69.85M▲ 66.9% | 66.5M▼ 4.8% | 31.94M▼ 52.0% | 22.57M▼ 29.3% | 19.06M▼ 15.6% | 28.6M▲ 50.0% | 59.49M▲ 0% |
Equity Growth % | - | 2983.33% | -35.55% | 66.92% | -4.79% | -51.97% | -29.33% | -15.56% | 50.03% | 468.42% |
Book Value per Share | -0.19 | 5.33 | 2.41 | 3.43 | 2.31 | 0.95 | 0.65 | 0.54 | 0.31 | 0.62 |
Total Shareholders' Equity | -2.25M | 64.94M | 41.85M | 69.85M | 66.5M | 31.94M | 22.57M | 19.06M | 28.6M | 59.49M |
Common Stock | 124 | 789 | 1K | 2K | 2K | 3K | 3K | 3K | 5K | 5K |
Retained Earnings | -2.26M | -15.51M | -41.11M | -70.92M | -109.98M | -172.41M | -185.74M | -193.81M | -216.21M | -221.52M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 5.28K | 21K | -297K | -138K | 76K | 140K | 781K | 363K | 370K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EQ Cash Flow Statement
Equillium, Inc. (EQ) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -662.2K | -7.53M | -22.95M | -24.62M | -32.08M | -8.73M | -21.78M | -19.03M | -22.75M | -18.88M |
Operating CF Margin % | - | - | - | - | - | -55.42% | -60.37% | -46.3% | - | - |
Operating CF Growth % | - | -1036.55% | -204.92% | -7.3% | -30.28% | 72.78% | -149.43% | 12.66% | -19.55% | -470.47% |
Net Income | -2.26M | -13.25M | -25.6M | -29.81M | -39.05M | -62.43M | -13.34M | -8.07M | -22.4M | -19.05M |
Depreciation & Amortization | 122 | 6.1K | 23K | 45K | 72K | 118K | 126K | 137K | 116K | 107K |
Stock-Based Compensation | 0 | 441.91K | 2.25M | 3.82M | 4.41M | 4.84M | 4M | 3.75M | 2.32M | 1.7M |
Deferred Taxes | 0 | 0 | 0 | -269K | 554K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.17M | 4.98M | -337K | 341K | 237K | 48.72M | -10.03M | -15.69M | -469K | 531K |
Working Capital Changes | 434.63K | 301K | 713K | 1.25M | 1.7M | 19K | -2.55M | 842K | -2.32M | -2.16M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -2.84M | -897K | 3.73M | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 842.72K | 775K | 894K | -1.58M | 2.51M | 723K | -2M | -1.94M | -1.88M |
Cash from Investing | -2.2K | -37.43M | -2.17M | -18.59M | 27.41M | 18.68M | -4.76M | 13.81M | 4.46M | -35K |
Capital Expenditures | -2.2K | -34.86K | -74K | -202K | -57K | -279K | -50K | -85K | -48K | -47K |
CapEx % of Revenue | - | - | - | - | - | 1.77% | 0.14% | 0.21% | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 700K | 0 | 0 | 12K | 12K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 7.77M | 66.37M | 9.84M | 53.95M | 31.06M | -1.22M | -9.23M | 164K | 30.43M | 65.68M |
Debt Issued (Net) | 7.77M | 1.6M | 9.88M | 0 | 0 | -1.43M | -9.13M | 0 | 0 | 0 |
Equity Issued (Net) | 100 | 64.47M | -156K | 53.78M | 29.91M | 0 | -260K | 164K | 30.43M | 65.68M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -156K | 0 | 0 | 0 | -260K | 0 | 0 | 0 |
Other Financing | 0 | 291.56K | 111K | 163K | 1.15M | 214K | 165K | 0 | 0 | 0 |
Net Change in Cash | 7.1M▲ 0% | 21.4M▲ 201.3% | -15.29M▼ 171.4% | 10.76M▲ 170.4% | 26.38M▲ 145.1% | 8.74M▼ 66.9% | -35.89M▼ 510.6% | -5.13M▲ 85.7% | 12.19M▲ 337.6% | 46.82M▲ 0% |
Free Cash Flow | -664.4K▲ 0% | -7.56M▼ 1038.0% | -23.02M▼ 204.5% | -24.83M▼ 7.8% | -32.14M▼ 29.5% | -9.01M▲ 72.0% | -21.83M▼ 142.3% | -19.11M▲ 12.5% | -22.79M▼ 19.3% | -18.93M▲ 0% |
FCF Margin % | - | - | - | - | - | -57.19% | -60.51% | -46.5% | - | - |
FCF Growth % | - | -1038.04% | -204.49% | -7.83% | -29.45% | 71.96% | -142.27% | 12.47% | -19.27% | -2.49% |
FCF per Share | -0.06 | -0.62 | -1.32 | -1.22 | -1.12 | -0.27 | -0.63 | -0.54 | -0.25 | -0.20 |
FCF Conversion (FCF/Net Income) | 0.29x | 0.57x | 0.90x | 0.83x | 0.82x | 0.14x | 1.63x | 2.36x | 1.02x | 0.99x |
Interest Paid | 0 | 0 | 142K | 0 | 0 | 847K | 946K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 580K | 0 | 0 | 0 |
EQ Key Ratios
Equillium, Inc. (EQ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -42.28% | -47.9% | -53.38% | -57.17% | -126.83% | -48.92% | -38.75% | -93.99% | -61.43% |
| Return on Invested Capital (ROIC) | -36.58% | -53.5% | -47.09% | -67.68% | -850.51% | -6017.4% | -804.9% | -8884.96% | 628.86% |
| Gross Margin | - | - | - | - | 100% | 100% | 100% | - | - |
| Net Margin | - | - | - | - | -396.14% | -36.96% | -19.63% | - | - |
| Debt / Equity | 0.00x | 0.23x | 0.14x | 0.18x | 0.32x | 0.04x | 0.02x | 0.03x | 0.01x |
| Interest Coverage | -4.18x | -90.76x | -26.13x | -35.40x | -58.29x | -24.98x | - | - | - |
| FCF Conversion | 0.57x | 0.90x | 0.83x | 0.82x | 0.14x | 1.63x | 2.36x | 1.02x | 0.99x |
| Revenue Growth | - | - | - | - | - | 128.97% | 13.89% | -100% | -100% |
Related:EQ Dividend History·EQ Revenue History·EQ Price History·EQ P/E History·EQ Financial Ratios·EQ Institutional Holders
EQ SEC Filings & Documents
Equillium, Inc. (EQ) SEC filings — annual & quarterly reports (10-K, 10-Q)
EQ Frequently Asked Questions
Equillium, Inc. (EQ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Equillium, Inc. (EQ) saw revenue decline by 100.0% over the past year.
Equillium, Inc. (EQ) reported a net loss of $19.1M for fiscal year 2025.
Dividend & Returns
Equillium, Inc. (EQ) has a return on equity (ROE) of -94.0%. Negative ROE indicates the company is unprofitable.
Equillium, Inc. (EQ) had negative free cash flow of $18.9M in fiscal year 2025, likely due to heavy capital investments.